WALTHAM, Mass., Jan. 13, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that the company granted a stock option to Eric Bouvier, the company’s newly appointed President and Chief Executive Officer, on January 9, 2012, the date that Dr. Bouvier commenced his employment with the company. The stock option was granted as an inducement material to Dr. Bouvier’s acceptance of employment with the company in accordance with NASDAQ Listing Rule 5635(c)(4), which, under these circumstances, provides an exception to the stockholder approval requirements and allows for the grant of this stock option to be made outside the company’s stockholder-approved equity plans.
